Capivasertib

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but with stricter controls. Biosimilars, including Humira’s, have struggled with adoption despite cost savings potential. Optum Rx also adds and removes various oncology and CNS medications for 2025.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but is subject to prior authorization. Biosimilars have struggled with low adoption despite cost advantages, but large PBMs like CVS Health are shifting towards biosimilars. Optum Rx also adds and removes various oncology and CNS medications from its 2025 formulary.

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.

CAPItello-281 Phase III trial results show AstraZeneca's Truqap (capivasertib) + abiraterone + ADT significantly improves rPFS in PTEN-deficient mHSPC patients, with early OS trend improvement. Trial continues for OS assessment.

Truqap, the first AKT inhibitor, has arrived in Korea, offering new hope for HR+/HER2- breast cancer patients with PIK3CA, AKT1, and PTEN mutations. Despite its potential, challenges like the domestic diagnostic environment and drug reimbursement limit its impact. Professor Park Kyong-hwa highlights unmet needs in HR+/HER2- treatment, Truqap's clinical benefits, and the importance of genetic analysis for precision medicine.

AstraZeneca's AKT inhibitor Truqap showed significant improvement in radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer patients, with an early trend towards overall survival improvement.

AstraZeneca's Phase III CAPItello-281 trial showed Truqap (capivasertib) + abiraterone + ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer. Early OS signs also suggest benefit, with ongoing trial for further assessment. Truqap + Faslodex was approved in the EU for ER-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations.

AstraZeneca's CAPItello-281 phase 3 trial showed significant improvements in radiographic progression-free survival (rPFS) with Truqap (capivasertib) combined with Zytiga (abiraterone) and ADT in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer patients, compared to Zytiga and ADT alone. The trial, involving over 1,000 patients, marks the first AKT inhibitor combination to demonstrate benefit in this specific form of prostate cancer, with ongoing assessment for overall survival.

AstraZeneca's Phase III CAPItello-281 trial showed Truqap improved radiographic progression-free survival (rPFS) when combined with abiraterone and androgen deprivation therapy (ADT) for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer. The combination also showed a promising trend towards improved overall survival (OS) compared to abiraterone, ADT, and placebo.

The article discusses the necessity of enabling JavaScript to run the app, as indicated by the noscript tag within the body of the HTML document.